Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBT (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of EBT data on record, last reported at -$20.4 million in Q3 2025.

  • For Q3 2025, EBT rose 32.74% year-over-year to -$20.4 million; the TTM value through Sep 2025 reached -$82.6 million, down 6.14%, while the annual FY2024 figure was -$68.4 million, 43.88% down from the prior year.
  • EBT reached -$20.4 million in Q3 2025 per ABEO's latest filing, up from -$23.7 million in the prior quarter.
  • Across five years, EBT topped out at -$8.3 million in Q2 2022 and bottomed at -$46.7 million in Q4 2021.
  • Average EBT over 5 years is -$17.9 million, with a median of -$15.5 million recorded in 2021.
  • Peak YoY movement for EBT: surged 71.9% in 2022, then crashed 164.61% in 2024.
  • A 5-year view of EBT shows it stood at -$46.7 million in 2021, then soared by 71.9% to -$13.1 million in 2022, then decreased by 1.56% to -$13.3 million in 2023, then crashed by 33.31% to -$17.8 million in 2024, then fell by 14.67% to -$20.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$20.4 million in Q3 2025, -$23.7 million in Q2 2025, and -$20.7 million in Q1 2025.